A significant increase in heart rate was noted in this SRM, as has previously been reported in people living with T2DM.24 Heart rate increase with tirzepatide was reportedly dose-dependent and higher than other GLP-1 receptor agonists, and the reason remains to be determined.25 Hence, it would be a good clinical practice to avoid the use of tirzepatide in people with tachyarrhythmias, which again tends to be more common in people with obesity. Here, GLP1R is linked to type 2 diabetes mellitus.